Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a gemini vitamin D analog

Cancer Prevention Research

Volumn 7, Issue 6, 2014, Pages 617-626

  Wahler, Joseph ^a   So, Jae Young ^a   Kim, Yeoun Chan ^a   Liu, Fang ^a,b,c   Maehr, Hubert ^a   Uskokovic, Milan ^a   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA,25 DIHYDROXY 21(3 HYDROXY 3 DEUTEROMETHYL 4,4,4 TRIDEUTEROBUTYL) 23 YNE 26,27 HEXAFLUOROCHOLECALCIFEROL; BXL 0124; CALCIUM; CYCLINE; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; GELATINASE A; GELATINASE B; KALININ; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MESSENGER RNA; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; 1,25-DIHYDROXY-21-(3-HYDROXY-3-METHYL-4,4,4-TRIBUTYL)-23-YNE-26,27-HEXAFLUOROCHOLECALCIFEROL; 1,25-DIHYDROXY-21-(3-HYDROXY-3-METHYLBUTYL)VITAMIN D(3); CALCITRIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BODY WEIGHT; BREAST CARCINOMA; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTRADUCTAL CARCINOMA; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; BREAST NEOPLASMS; CALCITRIOL; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; MICE, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903525024     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0362     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010;102:680-91.
3. Troester MA, Swift-Scanlan T. Challenges in studying the etiology of breast cancer subtypes. Breast Cancer Res 2009;11:104.
4. Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol 2011;13:767-73.
5. Pare R, Yang T, Shin JS, Tan PH, Lee CS. Breast cancer precursors: diagnostic issues and current understanding on their pathogenesis. Pathology 2013;45:209-13.
6. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009;7:511-22.
7. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010;107:12629-33.
8. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008;100:1643-8.
9. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170-8.
10. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
11. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005;103:1778-84. (Pubitemid 40563248)
12. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-4. (Pubitemid 40800525)
13. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:261-72.
14. Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Front Biosci (Landmark Ed) 2010;15:226-36.
15. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406. (Pubitemid 351609443)
16. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002;94:272-81. (Pubitemid 34049069)
17. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-61. (Pubitemid 43167123)
18. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227-31. (Pubitemid 11238851)
19. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007;103:708-11. (Pubitemid 46420519)
20. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990;19:614-22.
21. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000;60:4412-8. (Pubitemid 32103619)
22. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and antiinflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011;51:311-36.
23. Matthews D, LaPorta E, Zinser GM, Narvaez CJ, Welsh J. Genomic vitamin D signaling in breast cancer: insights from animal models and human cells. J Steroid Biochem Mol Biol 2010;121:362-7.
24. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA, et al. Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 2012;153:2576-87.
25. Lee HJ, Paul S, Atalla N, Thomas PE, Lin X, Yang I, et al. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res 2008;1:476-84.
26. So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, et al. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res 2013;6:959-70.
27. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, et al. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653-6.
28. So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, Maehr H, et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol 2011;79:360-7.
29. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000;92:1185-6.
30. So JY, Lee HJ, Kramata P, Minden A, Suh N. Differential expression of key signaling proteins in MCF10 cell lines, a human breast cancer progression model. Mol Cell Pharmacol 2012;4:31-40.
31. Maehr H, Lee HJ, Perry B, Suh N, Uskokovic MR. Calcitriol derivatives with two different side chains at C-20. V. Potent inhibitors of mammary carcinogenesis and inducers of leukemia differentiation. J Med Chem 2009;52:5505-19.
32. Lee HJ, Ju J, Paul S, So JY, DeCastro A, Smolarek A, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009;15:4242-9.
33. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, et al. Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 2006;72:332-43. (Pubitemid 43975086)
34. So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, Liu F, et al. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS ONE 2013;8:e54020.
35. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
36. Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 2002;16:693-706. (Pubitemid 34274039)
37. Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol 1999;206:88-99. (Pubitemid 29069876)
38. Smalley MJ, Titley J, O'Hare MJ. Clonal characterization of mouse mammary luminal epithelial and myoepithelial cells separated by fluorescence-activated cell sorting. In Vitro Cell Dev Biol Anim 1998;34:711-21.
39. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7. (Pubitemid 32223594)
40. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelialmesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010;15:201-12.
41. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8. (Pubitemid 27446075)
42. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5. (Pubitemid 24216953)
43. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006;20:2673-86. (Pubitemid 44498378)
44. Schnitt SJ. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res 2009;11:101.
45. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.BMCCancer 2010;10:483.
46. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011;223:307-17.